Entest Group Inc is a blank check company. The Company is formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses or entities. The Companyâ€™s current business plan is to seek new business opportunities or to engage in a business combination with an unidentified company. The Company has no operations and has not generated revenues.

Employees

Sector

Investment Holding Companies

More about the company

Market Closed - OTC Markets 23:29:04 07/01/2026 +04			5-day change	1st Jan Change
0.000200 ^USD	-80.00%		-.--%	-

21/01/20	Entest Group, Inc. Reports Earnings Results for the First Quarter Ended November 30, 2019	CI
20/12/19	Entest Group, Inc. Reports Earnings Results for the Full Year Ended August 31, 2019	CI

Market Cap	541K 481K 449K 409K 771K 52M 778K 5.43M 2.1M 26.58M 2.03M 1.99M 85.31M	P/E 2018	-0.92x	P/E 2019	12.6x
Enterprise Value	562K 499K 466K 425K 801K 54.03M 809K 5.64M 2.19M 27.62M 2.11M 2.06M 88.65M	EV / Sales 2018	-	EV / Sales 2019	-
Free-Float	98.54%	Yield 2018 *	-	Yield 2019	-

21/01/20	Entest Group, Inc. Reports Earnings Results for the First Quarter Ended November 30, 2019	CI
20/12/19	Entest Group, Inc. Reports Earnings Results for the Full Year Ended August 31, 2019	CI
15/07/19	Entest Group, Inc. Reports Earnings Results for the Third Quarter Ended May 31, 2019	CI
23/01/19	Entest Group, Inc. Reports Earnings Results for the First Quarter Ended November 30, 2018	CI
04/12/18	Entest Group, Inc. Announces Management Changes	CI
27/11/18	Peiwen Yu completed the acquisition of 48.3% stake in Entest Group, Inc. from Regen BioPharma, Inc., Bostonia Partners, Inc, Dunhill Ross Partners, Inc., Bio-Technology Partners Business Trust, David Koos and Sherman Family Trust.	CI
20/11/18	Peiwen Yu entered into an agreement to acquire 48.3% stake in Entest Group, Inc. from Regen BioPharma, Inc., Bostonia Partners, Inc, Dunhill Ross Partners, Inc., Bio-Technology Partners Business Trust, David Koos and Sherman Family Trust for $0.33 million.	CI
14/02/18	ENTB will Change its Name to ETNI	CI
27/11/15	Entest Group, Inc. Auditor Raises 'Going Concern' Doubt	CI
21/08/15	Entest Biomedical, Inc. will Change its Ticker to ENTB from ENTB.D	CI
27/07/15	Entest Biomedical, Inc. will Change its Ticker to ENTBD from ENTB	CI
16/07/14	Christine Ichim Joins Entest BioMedical Inc. as Director of Research	CI
06/03/13	Entest Biomedical Mulls Acquisitions	CI

21/01/20	ENTEST : Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)	AQ
08/01/20	ENTEST GROUP, INC. : Changes in Registrant's Certifying Accountant (form 8-K)	AQ
20/12/19	ENTEST : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K)	AQ
10/05/18	Entest Group, Inc. : Declares Property Dividend of 3,000,000 Common Shares of Zander Therapeutics Inc.	PR
13/09/17	Entest Biomedical : Zander Therapeutics, Inc. Announces Appointment of Dr. Robin Beat Gasser to Scientific Advisory Board	PR

Entest Group, Inc. Stock

Stocks

ETNI

US29383T3005

Investment Holding Companies

Valuation: Entest Group, Inc.

Chart: Entest Group, Inc.

Latest news: Entest Group, Inc.

Press Releases: Entest Group, Inc.

Quotes and Performance

Price Extremes

Managers and Directors: Entest Group, Inc.

Shell Companies

Financials

Company Profile

1 month	0		0.01
Current year	0		0.01
1 year	0		0.01
3 years	0		0.01
5 years	0		0.02
10 years	0		0.09

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ENTEST GROUP, INC.	-80.00%	-.--%	+100.00%	-66.67%	9.83K
INVESTOR AB	+1.09%	-1.71%	+31.99%	+91.57%	123B
INDUSTRIVÄRDEN AB	+0.86%	-3.93%	+38.74%	+82.04%	22.46B
HAL TRUST	-0.97%	-1.21%	+20.15%	+47.74%	16.61B
MERITZ FINANCIAL GROUP INC.	+1.26%	+2.55%	+13.58%	+133.33%	15.39B
LUNDBERG B	+0.62%	-3.72%	+15.19%	+24.86%	14.07B
KINGDOM HOLDING COMPANY	+0.07%	+2.98%	+73.14%	+89.45%	13.3B
INVESTMENT AB LATOUR	+0.30%	-3.59%	-11.55%	+7.10%	12.84B
BAJAJ HOLDINGS & INVESTMENT LIMITED	-2.26%	-3.25%	-12.17%	+48.37%	12.2B
WASHINGTON H. SOUL PATTINSON AND COMPANY LIMITED	-1.11%	-2.67%	+15.80%	+38.23%	11.93B
Average	-8.01%	-1.99%	+28.49%	+49.60%	24.15B
Weighted average by Cap.	+0.53%	-2.01%	+26.58%	+77.02%

	2018	2019
Net sales	-	-
Net income	-1.48M -1.31M -1.23M -1.12M -2.11M -142M -2.13M -14.83M -5.75M -72.61M -5.55M -5.43M -233M	192K 170K 159K 145K 273K 18.42M 276K 1.92M 745K 9.42M 719K 704K 30.22M
Net Debt	19.4K 17.24K 16.09K 14.66K 27.66K 1.86M 27.91K 195K 75.44K 953K 72.84K 71.26K 3.06M	21.2K 18.83K 17.58K 16.02K 30.22K 2.04M 30.5K 213K 82.43K 1.04M 79.58K 77.86K 3.34M